MKI67 and breast carcinoma: Thus, our future study will enroll a larger cohort of patients with breast cancer, grouped as previously described (low, ≤10% Ki-67-positive cells; intermediate, >10≤20% Ki-67-positive cells; and high, >20% Ki-67-positive cells) (28), to specifically evaluate the association between different Ki-67 protein expression levels and stem-like cells.